Antimicrobial Resistance: How to Foster Innovation, Access and Appropriate Use of Antibiotics? A Joint Technical Symposium by WHO, WIPO and WTO
Antimicrobial resistance is one of the most pressing challenges for humanity. It affects all areas of health, involves many sectors and has an impact on the whole of society. Increasing resistance threatens to roll back the achievements of modern medicine as many medicinal procedures rely on effective antibiotics. Antibiotics, more than other medicines, can be considered a public good for which society has a collective responsibility. The Symposium will offer a forum to exchange views and experiences, to achieve a better understanding of the global challenge of antimicrobial resistance and to envisage possible ways forward.
Date: 25 October 2016 Place: WIPO Headquarters, Geneva, Switzerland
Two innovative technologies for early infant diagnosis of HIV newly prequalified by WHO will allow many more infants to be diagnosed quickly and placed on life-saving treatment.
The products, Alere™ q HIV-1/2 Detect (made by Alere Technologies GmbH) and Xpert® HIV-1 Qual Assay (made by Cepheid AB) can be used to diagnose infants in as little as an hour, instead of sending a sample to a laboratory, which can take weeks or months to return a result.
Launch of new guidance to make children’s medicines safer and more effective
To address the gap in children’s medicines, the World Health Organization (WHO) and the International Pharmaceutical Federation (FIP) today release new guidelines for health care professionals prescribing or supplying medicines for children when no authorised product exists. The guidelines are available to all countries and professionals on the two organisations’ web sites.
People worldwide depend on the correct and competent behavior of a number of institutions and on manufacturers when they take their medicines. Those medicines must be of good quality, safe and effective. But largely due to human error, or, in some cases, pure profiteering, it happens that those institutions and manufacturers do not carry out their work adequately. The possible result of this is that risky or ineffective medicines may come to market, endangering patients or, at best, wasting precious health resources on treatments that don’t work.
Two resolutions related to access to health products were passed at the 69th World Health Assembly between 23-28 May. These resolutions aim to make quality health products more widely available and affordable and to reduce medicines and vaccines shortages in countries. In addition, the first ever list of Assistive Health Products was launched at a side event hosted by several governments.
News and events
17 - 21 October 2016
WHO Expert Committee on Specifications for Pharmaceutical Preparations
22 - 23 September 2016
Safe production of IPV
17 - 21 October 2016
Technical Briefing Seminar English